




<b>Name</b>	Gilles Salles, MD, PhD	
<b>Current Position</b>	Chief Attending, Lymphoma Service, Department of Medicine	
<b>Country</b>	United States of America	
<b>Major Field</b>	Lymphoma	

## Educational Background

Master Degree	Université Claude Bernard – Lyon-1 Lyon, France	11/1985 – 10/1986
M.D.	Université Claude Bernard – Lyon-1 Lyon, France	09/1978 – 07/1989
Ph.D. (Immunology)	Université Claude Bernard – Lyon-1 Lyon, France	10/1990 – 06/1994
Habilitation to Direct Research (Habilitation à Diriger des Recherches)	Université Claude Bernard – Lyon-1 Lyon, France	01/1990 – 01/1996
Specialization training in Oncology (Diplôme d'Etudes Spécialisées Complémentaire en Cancérologie)	Université Claude Bernard – Lyon-1 Lyon, France	09/1988 – 09/1990
Residency – Internal Medicine (Internat des Hôpitaux de Lyon)	Hospices Civils de Lyon (Lyon University Hospital) – Lyon, France	09/1984 – 09/1989
Research Fellow	Dana Farber Cancer Institute – Harvard Medical School – Boston, USA	10/1990 – 09/1992

## Professional Experience (Academic Appointments)

Assistant Professor (Chef de Clinique des Universités)	Faculté de Médecine Laënnec Université Claude Bernard – Lyon-1 Lyon, France	10/1992 – 04/1996
Assistant Professor – Fast Track (Praticien – Hospitalo-Universitaire)	Faculté de Médecine Laënnec Université Claude Bernard – Lyon-1 Lyon, France	05/1996 – 08/1996
Professor of Medicine - 2 <sup>nd</sup> Rank (2 <sup>ème</sup> Classe)	Faculté de Médecine Lyon-Sud Université Claude Bernard – Lyon-1 Lyon, France	09/1996 – 08/2007
Professor of Medicine - First Rank (1 <sup>ère</sup> Classe)	Faculté de Médecine Lyon-Sud Université Claude Bernard – Lyon-1 Lyon, France	09/2007 – 08/2014
Professor of Medicine - Exceptionnal Rank (Classe Exceptionnelle)	Faculté de Médecine Lyon-Sud Université Claude Bernard – Lyon-1 Lyon, France	09/2014 – 07/2020



Director of the University Research Team “Pathology of Lymphoid Cells” (EA 3737)	Université Claude Bernard – Lyon-1 Lyon, France	01/1999 – 12/2006
Director of the Research Team “Indolent B-Cell Proliferations” > within the Laboratory of Molecular Biology of the Cell (UMR5239)	Ecole Normale Supérieure de Lyon Lyon, France & Centre National de La Recherche Scientifique (CNRS) - France	01/2007 – 12/2015
Director of the Research Team “Clinical and Experimental models of Lymphomagenesis” > within the Cancer Research Center of Lyon (UMR1052)	Université Claude Bernard – Lyon-1 Lyon, France & Institut National de la Santé et de Recherche Médicale (INSERM), France	01/2016 – 07/2020
Member	Memorial Sloan Kettering Cancer Center, New York, NY	08/2020 – present
Professor of Medicine	Weill Cornell Medical College	08/2021 – present
<b>Professional Experience (Hospital Appointments)</b>		
Attending Physician (substitute) Blood Diseases Service	Hospices Civils de Lyon (Lyon University Hospital) Edouard Herriot Hospital Lyon, France	10/1989 – 09/1990
Assistant Professor Hematology Service	Hospices Civils de Lyon (Lyon University Hospital) Lyon-Sud Hospital Pierre Benite, France	10/1992 – 08/1996
Attending Physician Hematology Service	Hospices Civils de Lyon (Lyon University Hospital) Lyon-Sud Hospital Pierre Benite, France	09/1996 – 05/2008
Deputy Chief Hematology Service	Hospices Civils de Lyon (Lyon University Hospital) Lyon-Sud Hospital Pierre Benite, France	06/2008 – 08/2011
Chief Hematology Service	Hospices Civils de Lyon (Lyon University Hospital) Lyon-Sud Hospital Pierre Benite, France	06/2011 – 07/2020



Chief Attending Lymphoma Service Department of Medicine	Memorial Hospital for Cancer & Allied Diseases New York, NY	08/2020 – present
---	---	-------------------

## Other Experience and Professional Memberships

<b>Organization</b>	<b>Date (yyyy-yyyy)</b>
American Society of Hematology	1993 – present
American Society of Clinical Oncology	1993 – present
European Hematology Association	1994 – present
French Society of Hematology	1994 – present
Society of Hematologic Oncology	2017 - present

## Main Scientific Publications

Schuster SJ, Bishop MR, ... , **Salles G\***, Maziarz RT\*; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. **N Engl J Med.** 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1. PubMed PMID: 30501490. (\* co-senior authors).

Bachy E, Seymour JF, Feugier P, ... Tilly H, **Salles G.** Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long- Term Results of the PRIMA Study. **J Clin Oncol.** 2019; 37(31):2815-2824. doi: 10.1200/JCO.19.01073. Epub 2019 Jul 24. PMID: 31339826;

**Salles G,** et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study. **Lancet Oncol.** 2020; 21(7):978-988, PMID: 32511983.

Morschhauser F, Tilly H, Chaidos A, ... **Salles G.** Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. **Lancet Oncol.** 2020 Nov;21(11):1433-1442. doi: 10.1016/S1470-2045(20)30441-1. PMID: 33035457.

Sehn LH, **Salles G.** Diffuse Large B-Cell Lymphoma. **N Engl J Med.** 2021 Mar 4;384(9):842-858. doi: 10.1056/NEJMra2027612. PMID: 33657296.

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, **Salles G.** Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. **N Engl J Med.** 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14. PMID: 34904799.